Integrated therapy plus AI-enhanced contingency management shows promise for treating cannabis use disorder with co-occurring mental health conditions

Integrated cognitive-behavioral therapies improved psychiatric symptoms and reduced cannabis use, particularly for co-occurring depression and PTSD. Pharmacotherapies showed inconsistent benefits. ADHD-focused behavioral and stimulant approaches demonstrated promising cannabis use reductions. AI applications including machine-learning relapse prediction, remote contingency management delivery, and reinforcement-learning-based incentive optimization improved attendance and abstinence verification.

Systematic search of PubMed, PsycINFO, Embase, and Web of Science through October 2025. Included clinical studies and systematic reviews on tailored interventions for CUD with co-occurring depression, PTSD, anxiety, or ADHD, plus research on AI-driven contingency management. 38 studies met inclusion criteria.

Cannabis use disorder rarely exists in isolation. Most people with CUD have co-occurring mental health conditions, and treating one without the other typically produces poor outcomes. This review maps the evidence for integrated approaches and points toward AI as a practical way to scale personalized treatment.

The convergence of integrated psychotherapy and AI-powered treatment tools could transform CUD care from one-size-fits-all to genuinely personalized, addressing the dual challenge of psychiatric complexity and treatment scalability.

Systematic review format synthesizes heterogeneous studies. AI-enhanced contingency management research is still early-stage with small samples. Pharmacotherapy findings were inconsistent across studies. Publication bias possible.